MYSTIC, Conn., May 13 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at Rodman & Renshaw’s 6th Annual Global Investment Conference on Tuesday, May 18, 2010 at 9:50 am (London Time). This conference will be held at the Grosvenor House Hotel, London, UK.
A live audio webcast of the presentation will be available at the following URL:
http://www.wsw.com/webcast/rrshq17/amrn
About Amarin
Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company’s lead product candidate is AMR101 (ethyl icosapentate), has commenced enrollment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: | |
Investor Contact Information: | |
John F. Thero | |
Chief Financial Officer | |
In US: +1 (860) 572 4979 | |
Gitanjali Ogawa | |
The Trout Group | |
In U.S. +1 (646) 378-2949 | |
International Media Contact Information: | |
Mark Swallow or David Dible | |
Citigate Dewe Rogerson | |
In UK: +44 (0)207 638 9571 | |
SOURCE Amarin Corporation plc
